Author profile Matched by name
R.D. Haryuni
- Articles in Melola
- 2 (0 verified)
- Citations (OpenAlex)
- 0
- Journals
- Atom Indonesia
- Name in journal metadata
- Haryuni, R.D.
Publication summary
No verified articles yet: the summary counts only articles linked to this author through OpenAlex.
Facts, not a score: Melola does not rate authors or compute credit points. The summary counts only articles linked through OpenAlex; articles matched by name alone are listed separately and not counted. Melola covers Indonesian journals harvested through OAI-PMH, so publications elsewhere may be missing. How notices are checked.
Co-authors
12 authors · 50 co-authorship links
Hover or tap a name to highlight its co-authors. Double-click to open the author's page.
- Affiliation unknown
- Different organisations
- Same organisation
- Affiliation unknown
- Thicker line = more joint articles · bigger circle = more articles
Show as table
| Co-author | Organisation | Joint articles |
|---|---|---|
| M Ramli | Affiliation unknown | 2 |
| S Soenarjo | Affiliation unknown | 1 |
| C.N. Ardiyatno | Affiliation unknown | 1 |
| A. Mutalib | Affiliation unknown | 1 |
| A. Bahtiar | Affiliation unknown | 1 |
| Y. Harahap | Affiliation unknown | 1 |
| S. Hermanto | Affiliation unknown | 1 |
| V.Y. Susilo | Affiliation unknown | 1 |
| D. Haffid | Affiliation unknown | 1 |
| T Triningsih | Affiliation unknown | 1 |
| S Sutari | Affiliation unknown | 1 |
Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.
Where the co-authors are
No institution with a known location yet.
Verified articles (0)
None.
Matched by name, not verified (2)
These articles carry the same name in the journal metadata but are not linked to this author through OpenAlex. They may belong to someone else with the same name, so they are not counted in the summary.
-
Radiolabeled Antibody Fragment for Preparation of (177Lu-DOTA)m-PAMAM G3.0-F(ab’)2 trastuzumab as a Radiopharmaceutical for Cancer Therapy
-
Fragmentation of Nimotuzumab for Preparation of 125I-F(ab’)2-Nimotuzumab as a Precursor for Preparing 125I-F(ab’)2-Nimotuzumab-NLS Radiopharmaceutical for Cancer Therapy
Linked by: Same name as an existing author.